Can The EQ-5D Detect Meaningful Change? A Systematic Review

Payakachat, Nalin; Ali, Mir; Tilford, J.; Ali, Mir M; Tilford, J Mick
November 2015
PharmacoEconomics;Nov2015, Vol. 33 Issue 11, p1137
Academic Journal
journal article
Background: The EQ-5D is one of the most frequently used, generic, preference-based instruments for measuring the health utilities of patients in economic evaluations. It is recommended for health technology assessment by the National Institute for Health and Clinical Excellence. Because the EQ-5D plays such an important role in economic evaluations, useful information on its responsiveness to detect meaningful change in health status is required.Objective: This study systematically reviewed and synthesized evidence on the responsiveness of the EQ-5D to detect meaningful change in health status for clinical research and economic evaluations.Methods: We searched the EuroQol website, PubMed, PsychINFO, and EconLit databases to identify studies published in English from the inception of the EQ-5D until August 15, 2014 using keywords that were related to responsiveness. Studies that used only the EQ-VAS were excluded from the final analysis. Narrative synthesis was conducted to summarize evidence on the responsiveness of the EQ-5D by conditions or physiological functions.Results: Of 1401 studies, 145 were included in the narrative synthesis and categorized into 19 categories for 56 conditions. The EQ-5D was found to be responsive in 25 conditions (45 %) with the magnitude of responsiveness varying from small to large depending on the condition. There was mixed evidence of responsiveness in 27 conditions (48 %). Only four conditions (7 %) (i.e., alcohol dependency, schizophrenia, limb reconstruction, and hearing impairment) were identified where the EQ-5D was not responsive.Conclusion: The EQ-5D is an appropriate measure for economic evaluation and health technology assessment in conditions where it has demonstrated evidence of responsiveness. In conditions with mixed evidence of responsiveness, researchers should consider using the EQ-5D with other condition-specific measures to ensure appropriate estimates of effectiveness. These conditions should be a main focus for future research using the new EQ-5D version with five response levels.


Related Articles

  • Rationing: it would be NICE to consider patients' views. Speight, Jane; Reaney, Matt // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/31/2009, p297 

    The article offers the author's personal view on rationing health care and the cost effectiveness criteria set out by the National Institute for Health and Clinical Excellence (NICE) in Great Britain. Topics include NICE's appraisals of quality adjusted life years or QALYs by a method called...

  • NICE considers the patient.  // PharmacoEconomics & Outcomes News;2/21/2009, Issue 572, p3 

    The article reports on a study by the British National Institute for Health & Clinical Excellence (NICE), investigating how value, to patients, is explored when new health technologies are considered, and new guidance on engaging patients in decision surrounding prescribed medicines. The...

  • A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States. Mavranezouli, Ifigeneia // PharmacoEconomics;2010, Vol. 28 Issue 12, p1109 

    Economic evaluation of health technologies in the form of cost-utility analysis is increasingly advocated. The most common outcome measure in this type of analysis is the QALY. In order to estimate QALYs, appropriate utility values are required. The objective of this review was to identify and...

  • A stated preference binary choice experiment to explore NICE decision making. Tappenden, Paul; Brazier, John; Ratcliffe, Julie; Chilcott, James // PharmacoEconomics;2007, Vol. 25 Issue 8, p685 

    Objective: To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services.Method: A stated preference binary choice experiment was used to...

  • Health-Related Productivity Loss: NICE to Recognize Soon, Good to Discuss Now. Zhang, Wei; Anis, Aslam // PharmacoEconomics;May2014, Vol. 32 Issue 5, p425 

    The authors reflect on the decision of the Great Britain National Institute for Health and Care Excellence (NICE) of the social benefit of drugs, particularly health-related productivity loss. They emphasize the issues surrounding the measurement and valuation of productivity loss, including...

  • Value-Based Approaches to Healthcare Systems and Pharmacoeconomics Requirements in Asia. Kamae, Isao // PharmacoEconomics;2010, Vol. 28 Issue 10, p831 

    Asian healthcare systems are very diverse, representing cultures, political systems and economies from more than 30 countries with varying histories. Despite the diversity in the region, there has been enormous growth in health economics and outcomes research since the beginning of the 21st...

  • New Challenges for NICE. Upton, Julian // Pharmaceutical Executive;Feb2010, Vol. 30 Issue 2, p26 

    The article presents the challenges faced by the National Institute for Health and Clinical Excellence (NICE) to address application of cost-effective health resource allocation in Great Britain. It mentions the criticism faced by NICE concerning the quality-adjusted life year (QALY) as metric...

  • Should NICE'S threshold range for cost per QALY be raised? Towse, Adrian // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/31/2009, p268 

    The article argues that the National Institute for Health and Clinical Excellence should fund cost-effective treatments. Topics are the guidelines for quality adjusted life year (QALY), the willingness of taxpayers to support the treatment costs for end-of-life drugs, the opportunity costs that...

  • NICE recommendations submitted by Kennedy.  // PharmacoEconomics & Outcomes News;8/8/2009, Issue 584, p3 

    The article focuses on the recommendations submitted by Professor Sir Ian Kennedy to the British National Institute for Health and Clinical Excellence (NICE) for the inclusion of social benefits in the institute's appraisals structure. Kennedy believes that such benefits should not create an...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics